Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Renal insufficiency and hypertension as long-term complications in liver transplantation.
Monsour HP Jr, Wood RP, Dyer CH, Galati JS, Ozaki CF, Clark JH. Monsour HP Jr, et al. Among authors: galati js. Semin Liver Dis. 1995 May;15(2):123-32. doi: 10.1055/s-2007-1007269. Semin Liver Dis. 1995. PMID: 7544917 Review. No abstract available.
Improved method for transjugular liver biopsy.
Middlebrook M, Cohen AM, Wallace MJ, Clark J, Galati J. Middlebrook M, et al. Among authors: galati j. J Vasc Interv Radiol. 1999 Jun;10(6):807-9. doi: 10.1016/s1051-0443(99)70119-3. J Vasc Interv Radiol. 1999. PMID: 10392952 No abstract available.
The role of choledochoscopy in the diagnosis and management of biliary tract diseases.
Siddique I, Galati J, Ankoma-Sey V, Wood RP, Ozaki C, Monsour H, Raijman I. Siddique I, et al. Among authors: galati j. Gastrointest Endosc. 1999 Jul;50(1):67-73. doi: 10.1016/s0016-5107(99)70347-0. Gastrointest Endosc. 1999. PMID: 10385725
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.
Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS Jr, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Vainorius M, Terrault NA, Nelson DR, Fried MW, Manns MP; HCV-TARGET Study Group. Reddy KR, et al. Among authors: galati js. Aliment Pharmacol Ther. 2017 Jan;45(1):115-126. doi: 10.1111/apt.13823. Epub 2016 Oct 28. Aliment Pharmacol Ther. 2017. PMID: 27790729 Free article.
Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.
Agrawal M, Cohen-Mekelburg S, Kayal M, Axelrad J, Galati J, Tricomi B, Kamal K, Faye AS, Abrudescu P, Scherl E, Lawlor G, Sultan K, Lukin D, Colombel JF, Ungaro RC. Agrawal M, et al. Among authors: galati j. Aliment Pharmacol Ther. 2019 Mar;49(5):564-571. doi: 10.1111/apt.15107. Epub 2019 Jan 20. Aliment Pharmacol Ther. 2019. PMID: 30663075
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS Jr, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Saxena V, et al. Among authors: galati js. Hepatology. 2017 Oct;66(4):1090-1101. doi: 10.1002/hep.29258. Epub 2017 Sep 4. Hepatology. 2017. PMID: 28504842 Free PMC article.
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group. Welzel TM, et al. Among authors: galati js. Gut. 2017 Oct;66(10):1844-1852. doi: 10.1136/gutjnl-2016-311609. Epub 2016 Jul 13. Gut. 2017. PMID: 27418632 Free PMC article.
Protease inhibitor-based therapy for hepatitis C virus infection-why wait?
Galati JS. Galati JS. Gastroenterol Hepatol (N Y). 2012 Oct;8(10):674-6. Gastroenterol Hepatol (N Y). 2012. PMID: 24683375 Free PMC article. No abstract available.
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK; SPRINT-1 investigators. Kwo PY, et al. Among authors: galati js. Lancet. 2010 Aug 28;376(9742):705-16. doi: 10.1016/S0140-6736(10)60934-8. Epub 2010 Aug 6. Lancet. 2010. PMID: 20692693 Clinical Trial.
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. McHutchison JG, et al. Among authors: galati js. N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22. N Engl J Med. 2009. PMID: 19625712 Free article. Clinical Trial.
13 results
Jump to page
Feedback